Single crystal X-ray diffraction analysis (SCXRD) constitutes a universal approach for the elucidation of molecular structure and for the study of crystalline forms. However, the discovery of viable crystallisation conditions remains both experimentally challenging and resource intensive, in time and quantity of analyte(s). We report a robot-assisted, high-throughput method for the crystallisation of organic-soluble small molecules, employing only micrograms of analyte per experiment. This allows hundreds of crystallisation conditions to be screened in parallel, with minimal overall sample requirements. Crystals suitable for SCXRD analysis are grown from nanolitre droplets of a solution of analyte in organic solvent(s), each of which is encapsulated within an inert oil to control the rate of solvent loss. This encapsulated nanodroplet crystallisation methodology can also be used in the search for new crystal forms, as exemplified through both our discovery of a new (thirteenth) polymorph of the olanzapine precursor ROY and the SCXRD analysis of the "uncrystallisable" agrochemical dithianon.
Single crystal X-ray diffraction (SCXRD) allows for the direct analysis of crystalline small molecules, providing structural information with sub-Ångstrom resolution, 1 de novo absolute stereochemistry assignment (via anomalous dispersion) 2 and detailed information on intermolecular interactions and structural packing motifs. Modern in-house single crystal diffraction instrumentation (e.g. microfocus X-ray tubes, multi-layer focusing optics and very low noise area detectors) allows for the routine investigation of crystals, containing only light atoms, with dimensions ≈ 50 µm. 3 That, in combination with improved access to synchrotron radiation sources (e.g. remote access beamlines), 4 has allowed SCXRD to become a ubiquitous research technique for molecular analysis, given a suitable crystalline sample, with over 1 million crystal structures deposited with the Cambridge Crystallographic Data Centre (CCDC) as of 2019. 5 Most small molecules are capable of existing as crystalline solids, either as pure materials or in conjunction with other species (e.g. salts, hydrates, solvates or co-crystals), 6 and thus are theoretically amenable to SCXRD analysis. However, the growth of suitably sized, high quality, single crystals, remains experimentally challenging, with researchers still reliant on time consuming manual methods (i.e. solvent evaporation, exchange or diffusion experiments), 7 which typically take many weeks to complete and require milligrams of analyte per experiment.
Recently a number of approaches have been described that attempt to circumnavigate the problems associated with traditional small molecule crystal growth, whilst retaining the analytical power provided by diffraction based techniques. Fujita's "crystalline sponge" method relies on the longrange ordering of small organic "guest" molecules within a single crystal of a pre-prepared porous host, subsequent SCXRD analysis of this host-guest complex providing structural information on the guest molecule. 8, 9 However, due to weak host-guest interactions, the small molecule guest must be carefully paired with an appropriate host, whilst the physical separation of guest molecules precludes analysis of any potential intermolecular interactions or other solid state properties.
Electron diffraction (e.g. MicroED) has subsequently emerged as a technique for the analysis of crystalline small molecules, with electron diffraction patterns being obtained from small single 3 crystals (1-10 µm in each dimension). [10] [11] [12] However, the intensity of the electron beam causes rapid sample degradation via in situ radical generation, the crystals must be stable within the vacuum stage (precluding the study of hydrates and solvates) and the elucidation of absolute stereochemistry is far from routine (e.g. dynamical refinement). 13 Thus, SCXRD remains the analytical technique of choice for the study of small molecules, albeit hampered by the practical constraints of crystal growth. Easy access to single crystals, suitable for SCXRD, would therefore be a significant enabling step across the molecular sciences. Solution phase crystallisation commences with nucleation from a supersaturated solution followed by crystal growth. 14 Nucleation is a stochastic process that, especially in the case of heterogeneous nucleation, is heavily influenced by the local environment (e.g. solvent(s), impurities, contact surfaces and convection). Therefore, control is required over both the conditions of supersaturation and the number of nucleation sites present. The solid state energy landscape of a molecule can be further complicated by the existence of multiple crystalline forms (e.g. salts, hydrates, solvates, co-crystals or polymorphs). Hence, the discovery of successful crystallisation conditions requires the exploration of large volumes of experimental space. Despite considerable research into the development of new small molecule crystallisation techniques, the current state-of-the-art still requires the use of milligrams of analyte per experiment, or is restricted to specific molecular classes, restricting the experimentally accessible envelope. [15] [16] [17] [18] Herein, we discuss our use of high-throughput crystallisation techniques, initially developed for the macromolecular field, as a general method for the growth of single crystals of organic soluble small molecules on the nanoscale. Our enabling breakthrough involves the use of inert viscous oils to control the rate of solvent loss from nanolitre scale droplets of organic solvent, each containing a few micrograms small molecule analyte. Oil-encapsulation results in a slow increase in sample concentration up to and beyond the point of saturation, even for nanolitre scale droplets of volatile organic solvents. When combined with the restricted number of nucleation sites available in such small droplets, we observe the growth of high quality single crystals, with dimensions ≥ 20 µm.
These crystals are shown to provide excellent X-ray diffraction data sets on either in-house instrumentation or central facility beamlines.
We also show that Encapsulated Nanodroplet Crystallisation (ENaCt) experiments can be efficiently set-up via a suitable liquid handling robot, resulting in a semi-automated experimental approach in which hundreds of individual crystallisation experiments can be set-up within a few minutes. This high-throughput parallel screening approach allows for rapid exploration of crystallisation space, and thus reliable access to suitable crystals. This is demonstrated herein through the successful crystallisation and SCXRD analysis of fourteen structurally diverse molecules, including de novo absolute stereochemical analysis, polymorph discovery (including a hitherto unknown thirteenth polymorph of ROY (R18)) and the crystallisation of "uncrystallisable" substrates (dithianon).
Results and Discussion

Preliminary oil-encapsulated nanodroplet crystallisations
Nanoscale crystallisations are typically incompatible with the use of analyte solutions containing a high percentage of organic solvents, as rapid solvent evaporation occurs leading to deposition of the analyte as amorphous material. The rate of evaporative loss being proportional to the air-liquid interface surface area, and thus rapid in terms of percentage volume for a nanolitre scale droplet.
We postulated that the evaporative loss from a nanodroplet of organic solvent could be slowed by reduction of the air-liquid interface surface area by encapsulation of the nanodroplet within a droplet of oil. This slower, more controlled, concentration of the analyte would lead to improved crystal growth. Ideally, the oils employed would need to be viscous, in order to maintain droplet shape and therefore analyte solution encapsulation, have low vapour pressures to prevent evaporation, be poorly soluble in organic solvents and be chemically inert.
Thus, we undertook a series of preliminary oil-encapsulated nanodroplet crystallisation experiments which involved using a TTP LabTech mosquito® liquid handling robot to place 250 nL droplets of different test oils into a 96-well glass plate (Laminex™ Glass Base 100 Micron), into which 50 nL of a solution of a small organic molecule (5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY)) in an appropriate organic solvent was placed. ROY was chosen as a test substrate due to its propensity to form distinctively coloured crystals, facilitating visual analysis of the crystallisation process. The resulting 96-well plates were sealed (Laminex™ Glass Cover), stored at room temperature and each well examined periodically for crystal formation by polarising light optical microscopy. After several days, the formation of large numbers of crystals could be observed, many of which were single crystals of sufficient dimensions for SCXRD ( Figure 1 ), providing initial experimental support for our research postulate. 
Comparison of encapsulated versus non-encapsulated nanodroplet crystallisations
Based on these preliminary results we attempted to further validate our experimental design through a comparison of organic solvent based nanodroplet crystallisation conditions with and without oil-encapsulation, employing a set of five representative small molecule analytes (aspirin 1, Finally, suitable single crystals of each of the five compounds (1-5) were retrieved from their corresponding 96-well plates, mounted and analysed by SCXRD. In all cases data of high quality were recorded, to a minimum completeness of 99% at a minimum resolution of 0.84 Å on standard in house diffractometers using Cu Kα X-radiation (λ = 1.54184 Å). Molecular structures were then obtained through structure solution and refinement using the OLEX2 20 interface to the SHELX 21 suite of programs. Furthermore, the absolute stereochemical assignments were confirmed by successful refinement of the Flack parameter derived from anomalous dispersion measurements for both (R)-BINOL (4) and (S)-naproxen (5) (Figure 3) . Each structure is provided with selected crystallographic information.
To further validate the capability of the ENaCt protocol, it was subsequently applied to a broader set of chemical compounds (S1-S7). These experiments were further refined through the addition of small volumes (up to 100 nL) of a secondary solvent to the solution of analyte within the inert oil droplet, and the use of a wider range of inert oils, both expanding the protocol's experimental space sampling through fine tuning of the crystallisation conditions. In all cases suitable single crystals were successfully grown and subsequently analysed by SCXRD resulting in full structure solution and refinement coupled with absolute stereochemical assignments where appropriate (see Figure S1 ).
Polymorph screening of 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (ROY)
Following the success of our previous crystallisation experiments we applied our ENaCt protocol to a well-known problem in solid state chemistry, namely polymorphism. This is the phenomenon where a given compound may crystallise into different solid phases, differing only by the three-dimensional arrangement of molecules in space, that return to indistinguishable solution or liquid states. 22 The discovery of polymorphic forms is particularly suited to our ENaCt protocol as large numbers of crystallisation experiments can be undertaken in parallel, reducing the total number of person-hours required, with well-defined, yet different, conditions. Polymorphism is of particular relevance to the pharmaceutical industry as different polymorphs of a compound can have significantly different physical properties (e.g. solubility and stability). This is a particular concern for the preparation of active pharmaceutical ingredients (API) where such physical properties directly impact on the bioavailability of a compound. Thus, the early identification of accessible polymorphs of an API is of significant economic importance as an unexpected appearance of a previously unknown stable polymorphic phase can result in temporary market withdrawal pending reformulation. 23 We chose 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile (6), also known as ROY after the different (red, orange, yellow) colours exhibited by the various crystalline states. A synthetic precursor of the antipsychotic olanzapine, we envisaged this as an ideal test substrate for polymorph screening using our high-throughput platform. Since the discovery of the first polymorphs of ROY in 1998, it has been the target of numerous experimental and computational studies focusing on new polymorph discovery and prediction. This has resulted in 12 published polymorphs, 9 of which have been characterised by X-ray diffraction. [24] [25] [26] In order to screen for new and existing polymorphs of ROY, a large number of parallel experiments were undertaken in which nanodroplets of ROY solutions were encapsulated in a selection of inert oils. Individual experiments were checked for crystal growth periodically, with the first single crystals appearing after 12 hours. Suitable single crystals of ROY were obtained from a range of different experimental conditions. and new polymorphs (R18) of ROY (6) .
Four of the known ROY polymorphs (Y, R, ON and ORP) can be accessed through solution phase crystal growth, the others only arising directly or indirectly via melt experiments. Through the utilisation of our ENaCt protocol we were able grow single crystals suitable for SCXRD analysis for all four of the solution phase accessible polymorphs, with Y being the most commonly observed ( Figure   5 ).
Additionally, deep-red block shaped, crystals of ROY were observed which did not match the colour, morphology profile or unit cell of any of the known ROY polymorphs ( Figure 5 ). Full structural investigation by SCXRD (150 K, in-house X-ray diffractometer) confirmed this as a new polymorph of ROY (R18) that had not previously been reported experimentally or even predicted through computational methods and only the second polymorph of ROY to have a Z' value >1. R18 is the thirteenth polymorph of ROY to be discovered, the tenth to be fully characterised through SCXRD, returning ROY to the status of world record holder for the most polymorphic organic molecule.
The structural feature that is most characteristic of the different polymorphs of ROY is the twist angle (θ) (the SCNC torsion angle). In the structure of polymorph R18, which contains two crystallographically independent molecules in the asymmetric unit, the torsion angle θ is found to be reduced to just 10.2763(6) and 5.0085(3) degrees, respectively. These values place the two independent molecules of ROY in R18 in a very high energy conformation that does not appear in any of the previously reported crystal energy landscape calculations. 27 This result implies that computational CSP studies may need to explore higher energy conformational space than hitherto realised and that experimentally accessible, albeit yet to be observed, polymorphs of many other compounds may have eluded prediction by such methods. Therefore, the discovery of this new unpredicted polymorph of ROY further validates the power of our crystallisation methodology both as a polymorph discovery tool and as a method to refine future computational CSP studies.
Crystallisation of an "uncrystallisable" molecule, dithianon (7)
13 Finally, we wished to apply our ENaCt methodology to the crystallisation of a crystallographically challenging or previously deemed "uncrystallisable" sample. We envisaged that the high-throughput capability of ENaCt would allow for the rapid screening of diverse crystallisation conditions required to ensure the growth of a single crystal suitable for X-ray diffraction analysis of such a material. To this end we selected the functionalised naphthoquinone dithianon (5,10-dioxo-5,10dihydronaphtho[2,3-b] [1, 4] dithiine-2,3-dicarbonitrile (7)). Dithianon was first introduced in 1963 as a broad spectrum foliar fungicide and is still used for the control of fungal infections in commercial agriculture. 28 Dinnebier et al. have previously shown the existence of four different polymorphs of dithianon (forms 1-4) via refinement against high-resolution X-ray powder diffraction data sets.
However, no single crystal X-ray diffraction data set was reported due to "…the lack of single crystals of sufficient size and quality…", arising from the lack of strong intermolecular interactions in the solid state. 29 Thus, following our ENaCt methodology, 384 individual crystallisation experiments were undertaken. 14 The structural model, derived from the SCRXD data, confirmed that we had successfully obtained a single crystal of dithianon (polymorph 1). The structure suffers from minor disorder components, ascribed to stacking faults within the crystal. Further analysis of the structure within the software package CrystalExplorer 30 indicated the presence of only a small number of weak intermolecular interactions within the structure. Furthermore no interlayer component of the total energy framework exceeds 15 kJmol -1 (see SI). We propose that the presence of only weak interactions is the cause for the previously failed crystallisation attempts of dithianon using traditional methodologies. This demonstrates the capability of the ENaCt protocol to address even challenging crystallisation problems.
Conclusion
There is a requirement across the molecular sciences for a widely applicable, high-throughput, crystallisation method, which operates on the microgram scale. The ENaCt protocol, described herein, fulfils these requirements as a tailor made solution to the crystallisation problem. Our results, both the successful crystallisation of a diverse set of small molecules, including "uncrystallisables" (dithianon), and the exploration of the polymorphs of ROY, provides strong evidence for the potential of ENaCt as a general tool for the crystallisation of organic soluble small molecules. We anticipate that such facile access to high quality single crystals, through the rapid sampling of large areas of the solid state energy landscape, will provide significant future benefits to the molecular science community.
